Zenas BioPharma, Inc.
For the period ended Dec 31, 2025. Filed Mar 16, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 16, 2026
ZBIO$28.58+0.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits and Financial Statement Schedules
Item 15. Exhibits and Financial Statements.
| (1) | For a list of the financial statements included herein, see the Index to the Consolidated Financial Statements on page 159 of this Annual Report on Form 10-K, incorporated into this item by reference. |
| (2) | Financial statement schedules have been omitted because they are either not required, not appliable or the information is included in the consolidated financial statements or the notes thereto. |
| (3) | Exhibits: |
| | ||
| | | |
| Exhibit No. | | Description |
| | | |
| 3.1 | | Second Restated Certificate of Incorporation of Zenas BioPharma, Inc. (incorporated by reference to Exhibit 3.1 to the Form 8-K filed on September 16, 2024, File No. 001-42270) |
| | | |
| 3.2 | | Amended and Restated Bylaws of Zenas BioPharma, Inc. (incorporated by reference to Exhibit 3.2 to the Form 8-K filed on September 16, 2024, File No. 001-42270) |
| | | |
| 4.1 | | Specimen stock certificate evidencing shares of common stock (incorporated by reference to Exhibit 4.1 to the Registration Statement on Form S-1 filed on September 6, 2024, File No. 333-281713). |
| | | |
| 4.2 | | Fourth Amended and Restated Shareholders Agreement, among the Registrant and certain of its stockholders, dated May 3, 2024 (incorporated by reference to Exhibit 4.2 to the Registration Statement on Form S-1 filed on September 6, 2024, File No. 333-281713). |
| | | |
| 4.3 | | Description of Securities (incorporated by reference to Exhibit 4.3 to the Annual Report on Form 10-K filed on March 11, 2025, File No. 001-42270) |
| | | |
| 4.4 | | Registration Rights Agreement, by and between Zenas BioPharma, Inc. and InnoCare Pharma Inc., dated October 7, 2025 (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed on October 8, 2025, File No. 001-42270). |
| | | |
| 4.5 | | Form of Registration Rights Agreement, by and among Zenas BioPharma, Inc. and the investors party thereto (incorporated by reference to Exhibit 10.4 to the Current Report on Form 8-K filed on October 8, 2025, File No. 001-42270). |
| | | |
| 10.1+ | | License Agreement by and between Zenas BioPharma (Cayman) Limited and Xencor, Inc., dated September 23, 2020 (incorporated by reference to Exhibit 10.1 to the Registration Statement on Form S-1 filed on August 22, 2024, File No. 333-281713). |
| | | |
| 10.2 | | First Amendment to License Agreement by and between Zenas BioPharma, Inc. and Xencor, Inc., dated June 24, 2024 (incorporated by reference to Exhibit 10.2 to the Registration Statement on Form S-1 filed on August 22, 2024, File No. 333-281713). |
| | | |
| 10.3+ | | License Agreement by and between Zenas BioPharma (Cayman) Limited and Xencor, Inc., dated May 27, 2021(incorporated by reference to Exhibit 10.3 to the Registration Statement on Form S-1 filed on August 22,2024, File No. 333-281713). |
| | | |
| 10.4+ | | First Amendment to License Agreement by and between Zenas BioPharma (Cayman) Limited and Xencor, Inc., dated May 27, 2021 (incorporated by reference to Exhibit 10.4 to the Registration Statement on Form S-1 filed on August 22, 2024, File No. 333-281713). |
| | | |
| 10.5+ | | Second Amendment to License Agreement by and between Zenas BioPharma, Inc. and Xencor, Inc., dated May 27, 2021 (incorporated by reference to Exhibit 10.5 to the Registration Statement on Form S-1 filed on August 22, 2024, File No. 333-281713). |
| | | |
| 10.6+ | | License Agreement by and between the Registrant and Bristol-Myers Squibb Company, dated as of August 30, 2023 (incorporated by reference to Exhibit 10.6 to the Registration Statement on Form S-1 filed on August 22, 2024, File No. 333-281713). |
| | | |
| 10.7# | | Zenas BioPharma, Inc. 2020 Equity Incentive Plan (incorporated by reference to Exhibit 10.7 to the Registration Statement on Form S-1 filed on August 22, 2024, File No. 333-281713). |
| | | |
| 10.8# | | Amendment to Zenas BioPharma, Inc. 2020 Equity Incentive Plan (incorporated by reference to Exhibit 10.8 to the Registration Statement on Form S-1 filed on August 22, 2024, File No. 333-281713). |
| | | |
| 10.9# | | Amendment to Zenas BioPharma, Inc. 2020 Equity Incentive Plan (incorporated by reference to Exhibit 10.9 to the Registration Statement on Form S-1 filed on August 22, 2024, File No. 333-281713). |
| | | |
| 10.10# | | Form of Restricted Share Agreement under the Zenas BioPharma, Inc. 2020 Equity Incentive Plan (incorporated by reference to Exhibit 10.10 to the Registration Statement on Form S-1 filed on August 22, 2024, File No. 333-281713). |
| | | |
| 10.11# | | Form of Non-Qualified Stock Option Agreement (Non-Employee Directors) under the Zenas BioPharma, Inc. 2020 Equity Incentive Plan (incorporated by reference to Exhibit 10.11 to the Registration Statement on Form S-1 filed on August 22, 2024, File No. 333-281713). |
| | | |
| 10.12# | | Form of Non-Qualified Stock Option Agreement (Employees) under the Zenas BioPharma, Inc. 2020 Equity Incentive Plan (incorporated by reference to Exhibit 10.12 to the Registration Statement on Form S-1 filed on August 22, 2024, File No. 333-281713). |
| | | |
| 10.13# | | Form of Incentive Stock Option Agreement under the Zenas BioPharma, Inc. 2020 Equity Incentive Plan (incorporated by reference to Exhibit 10.13 to the Registration Statement on Form S-1 filed on August 22, 2024, File No. 333-281713). |
| | | |
| 10.14#† | | Zenas BioPharma, Inc. Short-Term Incentive Plan (as amended). |
| | | |
| 10.15# | | Zenas BioPharma, Inc. 2024 Equity Incentive Plan (incorporated by reference to Exhibit 4.6 the Form S-8 filed on September 16, 2024, File No. 333-282151) |
| | | |
| 10.16# | | Form of U.S. Non-Qualified Stock Option Agreement under the Zenas BioPharma, Inc. 2024 Equity Incentive Plan (incorporated by reference to Exhibit 10.16 to the Registration Statement on Form S-1 filed on September 6, 2024, File No. 333-281713). |
| | | |
| 10.17# | | Form of Global Non-Qualified Stock Option Agreement under the Zenas BioPharma, Inc. 2024 Equity Incentive Plan (incorporated by reference to Exhibit 10.17 to the Registration Statement on Form S-1 filed on September 6, 2024, File No. 333-281713). |
| | | |
| 10.18# | | Zenas BioPharma, Inc. 2024 Employee Stock Purchase Plan (amended and restated) (incorporated by reference to Exhibit 10.18 to the Annual Report on Form 10-K filed on March 11, 2025, File No. 001-42270) |
| | | |
| 10.19#† | | Zenas BioPharma, Inc. Non-Employee Director Compensation Policy (as amended January 1, 2026). |
| | | |
| 10.20 | | Zenas BioPharma, Inc. Non-Employee Director Compensation Policy (as amended July 7, 2025) (incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q filed on August 12, 2025, File No. 001-42270) |
| | | |
| 10.21# | | Amended and Restated Employment Agreement between the Registrant and Leon O. Moulder, Jr., dated September 4, 2024 (incorporated by reference to Exhibit 10.20 to the Registration Statement on Form S-1 filed on September 6, 2024, File No. 333-281713). |
| | | |
| 10.22# | | Amended and Restated Employment Agreement between the Registrant and Joseph Farmer, dated September 4, 2024 (incorporated by reference to Exhibit 10.21 to the Registration Statement on Form S-1 filed on September 6, 2024, File No. 333-281713). |
| | | |
| 10.23# | | Amended and Restated Employment Agreement between the Registrant and Jennifer Fox, dated September 4, 2024 (incorporated by reference to Exhibit 10.22 to the Registration Statement on Form S-1 filed on September 6, 2024, File No. 333-281713). |
| | | |
| 10.24# | | Amended and Restated Employment Agreement between the Registrant and Orlando Oliveira, dated September 4, 2024 (incorporated by reference to Exhibit 10.23 to the Registration Statement on Form S-1 filed on September 6, 2024, File No. 333-281713). |
| | | |
| 10.25#† | | Employment Agreement between the Registrant and Lisa von Moltke, dated February 17, 2025 |
| | | |
| 10.26 | | Form of Indemnification Agreement between the Registrant and each of its directors and executive officers (incorporated by reference to Exhibit 10.27 to the Registration Statement on Form S-1 filed on September 6, 2024, File No. 333-281713). |
| | | |
| 10.27 | | Consulting Agreement between the Registrant and Ting Xiao, dated June 10, 2025 (incorporated by reference to Exhibit 10.2 to the Quarterly Report on Form 10-Q filed on August 12, 2025, File No. 001-42270). |
| | | |
| 10.28+ | | Revenue Participation Right Purchase and Sale Agreement, by and between Zenas BioPharma, Inc. and Royalty Pharma Investments 2019 ICAV, dated September 2, 2025 (incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q filed on November 12, 2025, File No. 001-42270). |
| | | |
| 10.29 | | Form of Securities Purchase Agreement, by and among Zenas BioPhama, Inc. and the investors party thereto, dated October 7, 2025 (incorporated by reference to Exhibit 10.3 to the Current Report on Form 8-K filed on October 8, 2025, File No. 001-42270). |
| | | |
| 10.30 | | Subscription Agreement, by and between Zenas BioPharma, Inc. and InnoCare Pharma Inc., dated October 7, 2025 (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on October 8, 2025, File No. 001-42270). |
| | | |
| 10.31+† | | License Agreement by and between Zenas BioPharma, Inc. and InnoCare Pharma Inc., dated October 7, 2025. |
| | | |
| 10.32 | | Zenas BioPharma, Inc. 2026 Inducement Plan (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on December 15, 2025, File No. 001-42270). |
| | | |
| 10.33 | | Form of Non-Statutory Stock Option Agreement under the Zenas BioPharma, Inc. 2026 Inducement Plan (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed on December 15, 2025, File No. 001-42270). |
| | | |
| 10.34 | | Form of Restricted Stock Unit Agreement under the Zenas BioPharma, Inc. 2026 Inducement Plan (incorporated by reference to Exhibit 10.3 to the Current Report on Form 8-K filed on December 15, 2025, File No. 001-42270). |
| | | |
| 10.35 | | Form of Global Non-Statutory Stock Option Agreement under the Zenas BioPharma, Inc. 2026 Inducement Plan (incorporated by reference to Exhibit 10.4 to the Current Report on Form 8-K filed on December 15, 2025, File No. 001-42270). |
| | | |
| 10.36 | | Form of Global Restricted Stock Unit Agreement under the Zenas BioPharma, Inc. 2026 Inducement Plan (incorporated by reference to Exhibit 10.5 to the Current Report on Form 8-K filed on December 15, 2025, File No. 001-42270). |
| | | |
| 19.1† | | Insider Trading Policy. |
| | | |
| 21.1 | | Subsidiaries of the Registrant (incorporated by reference to Exhibit 21.1 to the Registration Statement on Form S-1 filed on September 6, 2024, File No. 333-281713). |
| | | |
| 23.1† | | Consent of Ernst & Young LLP, independent registered public accounting firm. |
| | | |
| 31.1† | | Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
| | | |
| 31.2† | | Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
| | | |
| 32.1* | | Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
| | | |
| 32.2* | | Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
| | | |
| 97.1 | | Policy for Recoupment of Incentive Compensation (Clawback) Policy (incorporated by reference to Exhibit 97.1 to the Annual Report on Form 10-K filed on March 11, 2025, File No. 001-42270). |
| | | |
| 101.INS† | | XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document |
| | | |
| 101.SCH† | | XBRL Taxonomy Extension Schema Document |
| | | |
| 101.CAL† | | XBRL Taxonomy Extension Calculation Linkbase Document |
| | | |
| 101.DEF† | | XBRL Taxonomy Extension Definition Linkbase Document |
| | | |
| 101.LAB† | | XBRL Taxonomy Extension Label Linkbase Document |
| | | |
| 101.PRE† | | XBRL Taxonomy Extension Presentation Linkbase Document |
| | | |
| 104† | | Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101) |
| † | Filed herewith. |
|---|
| # | Indicates management contract or compensatory plan. |
|---|
| + | Portions of this exhibit (indicated by asterisks) have been redacted pursuant to Item 601 S-K because they are both not material and the registrant customarily and actually treats such information as private of confidential. |
|---|
| * | This certification will not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent specifically incorporated by reference into such filing. |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.